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Abstract
Background: The deficit of pancreatic islet b cells caused by autoimmune destruction is a crucial issue in type 1 diabetes
(T1D). It is essential to fundamentally control the autoimmunity for treatment of T1D. Regulatory T cells (Tregs) play a
pivotal role in maintaining self-tolerance through their inhibitory impact on autoreactive effector T cells. An abnormality of
Tregs is associated with initiation of progression of T1D.
Methodology/Principal Findings: Here, we report that treatment of established autoimmune-caused diabetes in NOD mice
with purified autologous CD4
+CD62L
+ Tregs co-cultured with human cord blood stem cells (CB-SC) can eliminate
hyperglycemia, promote islet b-cell regeneration to increase b-cell mass and insulin production, and reconstitute islet
architecture. Correspondingly, treatment with CB-SC-modulated CD4
+CD62L
+ Tregs (mCD4CD62L Tregs) resulted in a
marked reduction of insulitis, restored Th1/Th2 cytokine balance in blood, and induced apoptosis of infiltrated leukocytes in
pancreatic islets.
Conclusions/Significance: These data demonstrate that treatment with mCD4CD62L Tregs can reverse overt diabetes,
providing a novel strategy for the treatment of type 1 diabetes as well as other autoimmune diseases.
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Introduction
Current stem cell-based therapy, along with islet transplantation
and promotion of b-cell regeneration by drugs and reprogram-
ming of adult pancreatic exocrine cells to b cells, are promising
approaches to treat type 1 diabetes (T1D) [1–7]. However,
autoreactive effector T cells may destroy these newly-generated
insulin-producing cells, thereby minimizing their therapeutic
potential. A major challenge for treatment of T1D is to identify
therapeutic approaches that fundamentally modulate autoimmune
responses. Regulatory T cells (Tregs) play a crucial role in
maintaining homeostasis and self-tolerance through their inhibi-
tory impact on autoreactive effector T cells [8–14], such as
releasing immunosuppressive cytokines interleukin-10 (IL-10)
and/or transforming growth factor-b (TGF-b). Although defects
of effector T cells [15–18] or antigen-presenting cells [19–23]
could play a role, increasing evidence demonstrates that
abnormalities of Tregs, either in cell number [24–26] or in
function [10,27–32], are associated with initiation and progression
of T1D, both in diabetic patients and animal models. Thus, the
manipulation of Tregs for treatment of T1D is an attractive
approach. Nevertheless, only a limited number of studies have
focused on restoration of impaired Treg function to confer
protection against autoimmune diabetes. We identified a novel
type of stem cells from human umbilical cord blood, designated
cord blood stem cells (CB-SC). Recently, we found that CB-SC
displayed immuno-modulatory effects on human allogeneic T
lymphocytes via in vitro co-culture with stem cells [3,33], the same
as mesenchymal stem cells derived from bone marrow [34]. Based
on this work, we hypothesized that CB-SC might also modulate
Treg function in autoimmune-caused T1D. Here, we report that
CB-SC can correct functional defects of mouse CD4
+CD62L
+
Tregs, leading to reversal of overt diabetes in an autoimmune-
caused diabetic NOD mouse model. These findings may have
implications for the development of novel human therapies.
Results
CB-SC modulation of NOD mouse regulatory T
lymphocytes
To investigate the therapeutic potential of Tregs in T1D, we
employed an experimental nonobese diabetic (NOD) mouse
model. Initially, we tested the co-culture of CB-SC and NOD
mouse spleen-derived lymphocytes and found that co-culture with
CB-SC did not significantly stimulate the proliferation of mouse
lymphocytes at different ratios of CB-SC:lymphocytes (1:5, 1:10,
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which is similar to the co-culture of CB-SC and human
lymphocytes [33]. Next, we analyzed co-cultures of CB-SC and
mouse lymphocytes for the presence of Tregs including conven-
tional CD4
+CD25
+ Treg and CD4
+Foxp3
+ Treg, and the
CD4
+CD62L
+ Treg. We found no significant differences in
CD4
+CD25
+ Treg and CD4
+Foxp3
+ Treg in total mouse spleen
lymphocytes that were either cultured alone or with CB-SC. In
contrast, the percentage of CD4
+CD62L
+ Treg was increased
about 5-fold after co-culture with CB-SC (Figure 1B). Further
flow cytometry revealed that only a very small proportion of these
CD4
+CD62L
+ Tregs was CD4
+CD25
+CD62L
+Foxp3
+ positive
(Figure 1C), and this percentage was not different between
lymphocytes co-cultured with or without CB-SC (0.1160.04% vs
0.1060.03%, P=0.44). We subsequently focused on
CD4
+CD62L
+ Tregs, which were primarily affected by co-culture
with CB-SC (designated CB-SC-modulated CD4
+CD62L
+ Tregs,
mCD4CD62L Tregs).
To document modulation of CD4
+CD62L
+ Tregs by CB-SC
after in vitro co-culture, intracellular cytokines related to helper T
(Th)1 and Th2 immune responses were measured using flow
analysis (Figure 1D). Results demonstrated that the IL-4 level was
significantly down-regulated (p=0.004), whereas IL-10, IL-12 and
TGF-b1 levels were up-regulated in mCD4CD62L Tregs
compared with control CD4CD62L Tregs (p=0.001, p=0.0001,
and p=0.006 respectively). In contrast, the IFN-c expression did
not change following co-culture with CB-SC (Figure 1D, p=0.5).
Next, we investigated expression of Th1-Th2-Th3 cell-related
genes by using quantitative real time PCR array in the purified
CD4
+CD62L
+ Tregs following co-culture with CB-SC. Results
demonstrated that mCD4CD62L Tregs displayed marked down-
regulation of Th cell-related genes including multiple cytokines
and their receptors, chemokines and their receptors, cell surface
molecules, along with signaling pathway molecules and transcrip-
tion factors (Table S1). These data clearly indicate that in vitro co-
culture with CB-SC causes substantial modifications of gene
expression in mouse CD4
+CD62L
+ Tregs, specifically for
function-related cytokine and chemokine genes.
CB-SC-modulated CD4
+CD62L
+ Tregs (mCD4CD62L
Tregs) correct hyperglycemia in overt diabetic NOD mice
Next, overt diabetic NOD mice (female, at 24–28 weeks of age)
were treated with mCD4CD62L Tregs (total 5 million cells/
mouse, i.p., n=8 mice) for 5–20 days after the diagnosis of T1D to
determine their therapeutic potential. The control CD4CD62L
Tregs at the same cell amount (i.p., n=5 mice) and vehicle PBS
(total 200 ml/mouse, i.p., n=5 mice) served as controls. Notably,
we found that treatment with mCD4CD62L Tregs restored
euglycemia in these overt diabetic mice (6/8 mice) (Figure 2A).
However, treatment with control CD4CD62L Tregs or PBS failed
to reduce hyperglycemia in diabetic mice (5/5, 5/5 mice
respectively) (Figure 2A). Diabetic mice that had been rendered
euglycemic after treatment with mCD4CD62L Tregs also showed
an improved glucose tolerance test (IPGTT), similar to that of
non-diabetic NOD mice at 7 weeks (Figure 2B). However,
diabetic mice treated with PBS or control CD4CD62L Tregs
maintained high glucose levels (.500 mg/dL) without any
observable down-regulation (Figure 2B). Moreover, we moni-
tored blood insulin levels 6 weeks after treatment with
mCD4CD62L Tregs. Results showed that insulin in diabetic mice
treated with control CD4CD62L Tregs or PBS vehicle was
undetectable by ELISA (0.019 ng/ml sensitivity for the ELISA kit,
Figure 2C). These mice had to be sacrificed because of severe
hyperglycemia (BG.600 mg/dL) and loss of body weight (.20%)
Figure 1. Flow analysis of CD4
+CD62L
+ Tregs following in vitro co-culture with human cord blood stem cells CB-SC. Mouse spleen
lymphocytes were isolated from female NOD mice (aged 6–8 weeks) and then co-cultured with CB-SC for 2–4 days at different ratios (A) or a ratio
1:10 of CB-SC:lymphocytes (B–D). Subsequently, the total lymphocytes were harvested for following cell count or flow analyses. Lymphocytes
cultured in absence of CB-SC served as control. (A) CB-SC have no significant effect on mouse lymphocyte proliferation during co-culture at different
ratios of CB-SC:lymphocytes. Data represent mean6s.d. of four experiments. (B) Percentage of CD4
+CD25
+ Treg, CD4
+Foxp3
+ Treg, and CD4
+CD62L
+
Treg after in vitro co-culture with CB-SC. (C) Flow analysis of CD25 and Foxp3 expressions in CD4
+CD62L
+ Tregs after in vitro co-culture with CB-SC.
(D) Flow analysis on CD4
+CD62L
+ Tregs after intra-cellular cytokine staining. Isotype-matched IgG served as control. Data in B–C are representative of
three to five experiments.
doi:10.1371/journal.pone.0004226.g001
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Committee (Figure 2D). In contrast, blood insulin levels in
diabetic NOD mice treated with mCD4CD62L Tregs were
significantly increased (Figure 2C, p=0.0025).
At 45 days after treatment, we subjected pancreata to
histological analysis and evaluated total b-cell mass followed by
immunostaining with insulin Ab on serial pancreatic sections.
Morphometric analysis demonstrated that treatment with
mCD4CD62L Tregs significantly increased total b-cell mass
(Figure 2E, p=0.0026). In contrast, b-cell mass was markedly
lower after vehicle PBS treatment or control CD4CD62L Treg
treatment (Figure 2E). To understand the mechanism of the
increase in total b-cell mass, we determined the expression of a cell
proliferation nuclear marker Ki67 [35] in pancreatic islets. Double
Figure 2. CB-SC-modulated CD4
+CD62L
+ Tregs (mCD4CD62L Tregs) reverse hyperglycemia in overt diabetic NOD mice. Mouse
spleen lymphocytes isolated from female NOD mice (aged 6–8 weeks) were co-cultured with CB-SC for cell sorting as described in methods. These
purified CD4
+CD62L
+ Tregs (mCD4CD62L Tregs) were used for treatment of spontaneously-developed autoimmune-caused diabetes in NOD mice.
The purified CD4
+CD62L
+ Tregs from lymphocytes not co-cultured with CB-SC (control CD4CD62L Tregs) served as control for mCD4CD62L Tregs.
Injection of vehicle PBS served as an additional control (n=5). (A) The mCD4CD62L Tregs correct hyperglycemia in diabetic NOD mice. Overt diabetic
NOD mice were treated with mCD4CD62L Tregs (total 5 million cells/mouse, i.p., red line; representative data are from 6 diabetic mice sensitive to
mCD4CD62L Treg treatment with euglycemia, n=8 mice). Purified control CD4CD62L Tregs served as control (total 5 million cells/mouse, i.p., blue
line, n=5 mice). PBS served as an additional control (black line, n=5 mice). (B) Intraperitoneal glucose tolerance testing (IPGTT) 3 weeks following the
1
st treatment with mCD4CD62L Tregs. Seven-week old NOD mice served as normal control. (C) Determination of blood insulin levels by ELISA. (D)
Effect of treatment on mouse body weight. (E–H) Pancreatic histology analyses: Pancreata from mCD4CD62L Treg-treated diabetic mice and control
mice were collected for immunohistochemistry after observation for 45 days. Representative sections are shown in each panel (G, H). (E)
Morphometric analysis of pancreatic b-cell mass. Pancreatic b-cell mass was determined by point-counting morphometry on insulin-positive islet b
cells followed by immunostaining with guinea pig anti-insulin Ab (Dako) and counter-staining with hematoxylin. (F) Quantification of Ki67-positive
cells in pancreatic islets after double immunostaining with Ki67 and insulin Abs. Isotype-matched rabbit IgG served as control for rabbit anti-Ki67
mAb. (G) Confocal microscopy shows double-immunostaining for insulin (red) and a cell proliferation nuclear marker Ki67 (green) (scale bar, 50 mm),
with a high magnification (two bottom rows, scale bar 10 mm). Control CD4CD62L Treg-treated diabetic mice (top panels) showed the Ki67-positive
cells distributed in the infiltrated inflammatory cells (blue, with high density), not in b-cell area (dashed pink circle), with almost complete
disappearance of b cells (red). (H) Double-immunostaining for b-cell marker insulin (red) and a-cell marker glucagon (green), followed by nuclear
counter-staining with DAPI (blue). Seven-week old NOD mice served as non-diabetic control to show normal islet architecture. Scale bar, 50 mm.
doi:10.1371/journal.pone.0004226.g002
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cells/islet expressed Ki67 in pancreatic islets of mCD4CD62L
Treg-treated mice (Figure 2F and G), which was much higher
than that in pancreatic islets of mice treated with control
CD4CD62L Tregs (160.4) (p=0.0014). It suggests that de novo
proliferation of b cells accounts for the noted increase in total b
cell mass. Moreover, double immunostaining with b-cell-marker
insulin and a-cell-marker glucagon revealed that pancreatic islets
in diabetic mice treated with mCD4CD62L Tregs displayed a
similar pattern of a- and b-cell distribution as that noted in normal
islets of non-diabetic NOD mice (Figure 2H). However, islet
architecture was completely destroyed with almost complete
disappearance of b cells in the diabetic mice treated with control
CD4CD62L Tregs (Figure 2H). Thus, treatment with
mCD4CD62L Tregs can correct hyperglycemia of T1D mice by
promoting b-cell regeneration and reconstitution of islet cell
architecture.
Treatment with mCD4CD62L Tregs reverses insulitis and
immune dysfunction in NOD mice
To establish whether mCD4CD62L Tregs exert an immuno-
suppressive influence on autoreactive effector T cells, we
performed pancreatic histological analysis and scored insulitis at
45 days after treatment. Histological evaluations showed that
approximately 80% of islet b cells (profound insulitis) were
destroyed in diabetic NOD mice prior to treatment. Six weeks post
treatment, we found that in diabetic mice receiving mCD4CD62L
Tregs, 36% of islets had no or few signs of infiltration of
inflammatory cells; 20% of islets displayed mild insulitis; 15% of
islets exhibited moderate insulitis; 18% of islets had severe insulitis
and only 11% of islets showed profound insulitis (Figure 3A and
B). The insulitis-free islets were of smaller size and positive for the
proliferation marker Ki67 (data not shown), suggesting that these
islets may have been newly generated. In contrast, all pancreatic
islets in diabetic mice receiving control CD4CD62L Tregs showed
massive infiltration of inflammatory cells and severe destruction of
pancreatic architecture (Figure 3A), and had few or no insulin-
positive cells present. Similarly, pancreatic histological examina-
tion demonstrated that those two mice (2/8 mice) that were
resistant to mCD4CD62L Tregs treatment also displayed
profound insulitis (data not shown) after 45 days observation.
To understand the molecular mechanism underlying reduction
of insulitis, we measured plasma Th1/Th2 cytokine levels by
ELISA. We found that Th1 cytokine IFN-c and Th2 cytokine IL-4
were considerably reduced in the plasma of mCD4CD62L Treg-
treated diabetic mice relative to control CD4CD62L Treg-treated
diabetic mice (P=0.017, Figure 3C; P=0.018, Figure 3D
respectively). In contrast, diabetic mice receiving mCD4CD62L
Tregs showed a marked increase in plasma IL-10 level compared
with those treated with control CD4CD62L Tregs (P=0.016;
Figure 3E) and non-diabetic NOD mice at age of 6 weeks
(P=0.014; Figure 3E). Additionally, plasma TGF-b1 level was
significantly elevated in mCD4CD62L Treg-treated diabetic mice
compared with control CD4CD62L Treg-treated diabetic mice
(P=0.041; Figure 3F). These data suggest that both IL-10 and
TGF-b1 may contribute to an induction of immune tolerance after
treatment with mCD4CD62L Tregs [36–38]. These data
demonstrate that exposure to CB-SC induced profound changes
in mCD4CD62L Tregs that helped restore ‘‘normal’’ islet
architecture and b-cell function resulting in the suppression of
diabetes.
TGF-b1 is one of the best characterized cytokines contributing
to the induction of immune suppression and maintaining of self-
tolerance [36]. To elucidate de novo molecular mechanism
underlying the protection of islet b cells following treatment with
mCD4CD62L Tregs, we determined TGF-b1 expression in
pancreatic islets by immunohistochemistry in addition to plasma
TGF-b1 measurement (Figure 3F). Results demonstrated that
TGF-b1 was presented at higher level in pancreatic islets of
mCD4CD62L Treg-treated diabetic mice compared with control
CD4CD62L Treg-treated diabetic mice (Figure 4A and B).
Staining of TGF-b1-positive cells showed two patterns: one was
distributed among islet b cells, with average positive cell number of
1469 cells/islet, and another was located around islet b cells.
Importantly, we found that these surrounding TGF-b1-positive
cells (negative for macrophage marker F4/80, but positive for
dendritic cell marker CD11c [39], data not shown), along with
their released TGF-b1 in the matrix (faint staining), formed a ring
surrounding pancreatic islets (Figure 4A). This ring may protect
newly-generated islets against attack by inducing apoptosis of auto-
aggressive effector lymphocytes, as determined by terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining (Figure 4B,5 8 623 TUNEL
+ infiltrated leukocytes in
mCD4CD62L Treg-treated group vs. 963 TUNEL
+ infiltrated
leukocytes in control CD4CD62L Treg-treated group, p=0.02).
To clarify which cell type became apoptotic, we performed double
staining with different cell markers including CD4 for CD4
+ T
cells, CD8 for CD8
+ T cells, B220 for B cells, and F4/80 for
macrophages respectively in combination TUNEL staining. We
found that treatment with mCD4CD62L Tregs increased the
apoptosis of infiltrated T cells, B cells, and macrophages compared
with control CD4CD62L Treg treatment (p=0.0034, p=0.024,
p=0.041, and p=0.032 respectively). In comparison with the
other three cell types however, CD4
+ T cells showed a much
higher percentage of apoptotic cells (Figure 4C). Thus, these data
suggest that treatment with mCD4CD62L Tregs enhances
expression of TGF-b1 in pancreatic islets that may contribute to
local protection of newly-generated pancreatic islets from the re-
destruction of autoreactive immune cells.
Discussion
Millions of T1D patients worldwide must have daily insulin
injections to survive. However, it is not a cure; it does not halt the
persistent autoimmune response. Nor can it reliably prevent
devastating complications such as neuronal and cardiovascular
diseases, blindness, and kidney failure. This compelling need
brings a sense of urgency to find a cure for T1D that can not only
overcome the shortage of insulin-producing b-cells, but also halt
the progression of autoimmunity [1,5,40]. Here we demonstrate
that treatment with autologous mCD4CD62L Tregs can reverse
established T1D, not only by controlling the autoimmunity but
also by promoting b-cell regeneration leading to the restoration of
euglycemia in a diabetic NOD mouse model. Thus, these findings
provide a new approach for the treatment of T1D.
Tregs are fundamental in controlling immune responses and
inducing self-tolerance. Functional defects of Tregs, not numerical,
are essential for the development of T1D [10,28–31]. In this study,
we found that the frequency of Tregs such as CD4
+CD25
+ Treg,
CD4
+CD25
+ Foxp3 Treg, and CD4
+CD62L
+ Treg failed to show
significant differences at different stages of diabetes in comparison
with pre-diabetic and/or non-diabetic NOD mice (data not
shown). Additionally, treatment with control CD4CD62L Tregs
could not reverse diabetes onset. Therefore, these data imply that
the intrinsic functional defects of Tregs in NOD mice are
consistent with previous reports [10,28–30]. To date, little is
known about how to correct the functional defects of Tregs. Based
on our previous work [33], our current study demonstrated that
Reverse T1D by mCD4CD62L Treg
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CD4
+CD62L
+ Tregs after coculture with CB-SC. Moreover, overt
diabetic mice treated with the purified mCD4CD62L Tregs
showed an elimination of hyperglycemia and a marked improve-
ment in insulin production, which is correlated with a significant
increase in b-cell mass and proliferation of b cells. Mechanistic
studies demonstrated that control of diabetes was correlated with
systemic immune alterations including restoration of Th1/Th2
cytokine balance in blood, as well as local regulations in pancreatic
islets through a unique distributional pattern of TGF-b1 that may
protect islet b cells against the infiltrated lymphocytes. These data
have demonstrated human cord blood stem cells CB-SC can
correct functional defects of CD4
+CD62L
+ Tregs and restore their
therapeutic potential to treat T1D.
Our immunostaining results showed that recent onset of diabetic
NOD mice possess a low amount of b-cell mass before treatment
(.80% destroyed), with a low frequency of proliferating beta cells.
Notably, treatment with mCD4CD62L Tregs can strongly stimulate
the proliferation of b cells that were double positive for insulin and a
cell proliferation nuclear antigen Ki67. This resulted in restoration of
total b-cell mass and reconstitution of normal pancreatic islet
architecture. It implies that mCD4CD62L Tregs function not only
Figure 3. Treatment with mCD4CD62L Tregs reverses insulitis and immune dysfunction in diabetic NOD mice. Overt diabetic NOD
mice treated with mCD4CD62L Tregs were sacrificed for pancreatic histological analysis and evaluation of blood cytokine levels after observation for
45 days (n=8). The control CD4CD62L Treg-treated diabetic mice (n=5) and PBS-treated diabetic mice (n=5) served as controls. (A and B) Treatment
with mCD4CD62L Tregs corrects insulitis in overt type 1 diabetic NOD mice. Representative data are from 6 diabetic mice (6/8 mice) sensitive to
mCD4CD62L Treg treatment with euglycemia. (A) Scoring of insulitis. Pancreatic islets were scored for % mononuclear cell infiltration after
immunostaining for insulin and counter-staining with hematoxylin as described in methods. (B) Representative images for different type of insulitis.
Data were collected from mCD4CD62L Treg-treated diabetic NOD mice. Scale bar, 50 mm. (C) Determination of plasma IFN-c level by ELISA. Non-
diabetic NOD mice at age of 6 weeks served as normal control. (D) Measurement of plasma IL-4 level by ELISA. (E) Determination of plasma IL-10 level
measured by ELISA. (F) Determination of plasma TGF-b1 level measured by ELISA. Data are shown as mean6s.d. of mouse plasma cytokine levels
from three experiments.
doi:10.1371/journal.pone.0004226.g003
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a pancreatic islet b-cell stimulator to promote b-cell regeneration.
Therefore, both key issues (autoimmunity and shortage of insulin-
producing cells) for recent onset of T1D have been overcome
simultaneously by the treatment with mCD4CD62L Tregs. For late-
s t a g eT 1 D ,i tw i l lb en e c e s s a r yt oc o m b i n em C D 4 C D 6 2 LT r e g sw i t h
stem cell-derived insulin-producing cells and/or other b-cell
surrogates due to the almost complete disappearance of b cells in
severe diabetics. Thus, early treatment with mCD4CD62L Tregs is
more effective in reversing T1D.
Application of autologous cells is an attractive strategy for cell-
based therapies as it eliminates the problems of immune rejection
and shortage of suitable donors. However, it is crucial to use
healthy allogeneic stem cells to modulate intrinsic functional
defects of patient’s Tregs due to the potential defects of patient’s
stem cells (un-published data). To generate a large-scale culture of
allogeneic stem cells, we have identified and characterized a
unique type of stem cell (CB-SC) from human umbilical cord
blood using a simple isolation technique (blood mononuclear cells
that attach to non-tissue cultured-treated Petri dishes [3]). In
comparison with using bone marrow-derived mesenchymal stem
cells (MSC) for immune modulation [34,41], application of CB-SC
possess several unique advantages including large resources of cord
blood worldwide, no risk to the donor, easy to culture and expand
Figure 4. Treatment with mCD4CD62L Tregs enhance expression of TGF-b1 in pancreatic islets. Overt diabetic NOD mice treated with
mCD4CD62L Tregs were sacrificed for pancreatic immunohistochemistry studies after observation for 45 days (n=8). Representative data are from 6
diabetic mice (6/8 mice) sensitive to mCD4CD62L Treg treatment with euglycemia. The control CD4CD62L Treg-treated diabetic mice served as
control (n=5). (A) TGF-b1 staining surrounds a pancreatic islet of mCD4CD62L Treg-treated diabetic mice, as determined by double-immunostaining
for TGF-b1 (yellow) and insulin (red). TGF-b1 positive cells (bright yellow) and released TGF-b1 in matrix (faint yellow) were distributed in the islet b
cell area (red) and surrounded islet b cells (top panels, scale bar 50 mm). High magnification is shown in bottom panels, scale bar 10 mm. Isotype-
matched mouse IgG1 served as a negative control for TGF-b1 immunostaining in a serial pancreatic section. Representative images were obtained
from five experiments. (B) TUNEL assay. The proteinase K-pretreated pancreatic slides were initially immunostained with TGF-b1 (yellow) and insulin
(red) Abs, followed by TUNEL assay (green), and nuclear counterstaining with DAPI (blue). Scale bar 20 mm. Representative images were obtained
from four experiments. (C) Percentage of apoptotic cells in subtypes of infiltrated leukocytes in pancreatic islets. Cryosections (8 mm thickness) of
frozen pancreata from mCD4CD62L Treg-treated diabetic mice (n=4) and control mice (n=4) were initially detected with In Situ Cell Death Detection
Kit (Roche), followed by immunostaining with different monoclonal Abs and imaging with a Zeiss LSM 510 META confocal microscope. Cryosections
incubated with label solution without the TUNEL reaction mixture and/or isotype-matched IgG served as negative controls. Data represent
mean6s.d. of five experiments.
doi:10.1371/journal.pone.0004226.g004
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specifically, CB-SC tightly adhere to culture dishes with a large
rounded morphology and are resistant to regular detaching
method (trypsin/EDTA), it is easy to collect suspending lympho-
cytes after co-culture with a minimum CB-SC contamination
(,1%) [3,33]. Thus, co-culture with CB-SC represents an ideal
co-culture model to study the stem cell-related immune regulation.
In current study, it is unfeasible to generate a large scale of stem
cells from mouse cord blood due to the limited blood volume
(about 10 ml/mouse). Therefore, we use CB-SC to co-culture with
NOD lymphocytes and investigate the therapeutic potential of
Tregs. During co-culture, CD4CD62L Tregs can be ‘‘educated’’
by the favorable microenvironment created by CB-SC through
cell to cell contact and soluble mediators [33]. After co-culture
with CB-SC, only floating lymphocytes were collected for
purification of mCD4CD62L Tregs. Thus, these mCD4CD62L
Tregs are the autologous therapeutic product.
In conclusion, we have developed a unique approach to reverse
established type 1 diabetes by using human CB-SC to modulate
autologous CD4CD62L Tregs. This treatment not only eliminated
hyperglycemia and restored islet architecture via a marked
increase in b-cell proliferation, but also diminished the autoim-
munity through systemic immune alterations and local regulations
in pancreatic islets. These autologous mCD4CD62L Tregs can be
readily generated by co-culture with allogeneic CB-SC for
therapeutic applications without concern for immune rejection.
Our findings outline a new strategy for the prevention and
treatment of diabetes and other autoimmune diseases.
Materials and Methods
Mice
Female NOD/LtJ mice, aged 5–6 weeks, were purchased from
Jackson Laboratories (Bar Harbor, ME) and maintained under
pathogen-free conditions at the University of Illinois at Chicago.
Blood glucose levels were monitored using an Ascensia ELITE
glucometer (Bayer Corporation, Elkhart, IN) between 9 and 11
A.M. under nonfasting conditions. Female diabetic NOD/LtJ
mice (at 24–28 weeks of age) with spontaneously-developed
autoimmune diabetes as confirmed by weight loss, polyuria, and
nonfasting blood glucose levels .250 mg/dL for at least 2
consecutive days [9,13,42,43], were used for treatment, according
to a protocol approved by the Animal Care Committee (ACC) of
University of Illinois at Chicago.
Stem cell culture and co-culture with lymphocytes
Human umbilical cord blood (60–120 ml/unit/bag) was
purchased from Life-Source Blood Services (Glenview, IL), which
were derived from healthy donors. Application of cord blood for
our researching does not need the ethical approval from the
University and sign any agreements with donors due to their
commercial availability. Human cord blood-derived stem cells
(CB-SC) were generated as previously described [3]. In brief, cord
blood mononuclear cells were plated in 150615 mm Petri dishes
(Becton Dickinson Labware, Franklin Lakes, NJ, not tissue culture-
treated dishes) at 1610
6cells/ml, 25 ml/dish in RPMI 1640
medium supplemented with 7% fetal bovine serum (Invitrogen,
Carlsbad, CA), and incubated at 37uC, in 8% CO2. After 2–3
weeks, CB-SC growing at 80–90% confluence were co-cultured
with mouse lymphocytes after removing all unattached cord blood
mononuclear cells. For co-culture, mouse lymphocytes were
isolated from 6–8 week-old NOD mouse spleens [33] and plated
onto CB-SC at a ratio 1:10 of CB-SC:lymphocytes in 150615 mm
Petri dishes containing 25 ml RPMI 1640 medium supplemented
with 7% fetal bovine serum (Invitrogen), and incubated at 37uCi n
an incubator with 8% CO2. After co-culture for 2–4 days, the
suspending lymphocytes were collected for experiments with a
minimum CB-SC contamination (,1% of floating cells were
positive for a CB-SC marker human leukocyte common antigen
CD45). Because CB-SC tightly adhere to the culture dishes and
exhibit large rounded morphology, it is easy to distinguish
lymphocytes from CB-SC and to collect them. In control
experiments, lymphocytes were cultured in identical growth
conditions but without CB-SC.
Flow analysis and cell sorting
Flow analysis and cell sorting were performed as previously
described [33]. For flow analysis, cells were incubated with rat
anti-mouse CD16 monoclonal antibody (eBioscience, San Diego,
CA) diluted in medium containing 2.5% horse serum (Vector
Laboratories) for 15 min at 4uC to block Fc receptor and to
prevent non-specific staining. Cells were incubated with rat anti-
mouse monoclonal antibodies (eBioscience), including Alex FluorH
647-conjugated CD3, FITC- or phycoerythrin (PE)-conjugated
CD4, FITC-conjugated CD25, and/or phycoerythrin-Cy7 (PE-
Cy7)-conjugated CD62L for 45 min at 4uC and then washed with
cold PBS prior to flow analysis. Isotype-matched rat anti-mouse
IgG antibodies (eBioscience) served as negative control. After
staining, cells were analyzed using a CyAn ADP (DakoCytoma-
tion). For intra-cellular cytokine staining, cells were initially stained
for cell surface antigens (e.g., PE-conjugated CD4, FITC-
conjugated CD25, and PE-Cy7-conjugated CD62L) and then
prepared by using a BD Cytofix/Cytoperm Fixation/Permeabi-
lization kit (BD Biosciences, San Jose, CA). Subsequently, cells
were stained with different combinations of antibodies including
FITC-conjugated IL-4, Alexa FluorH 647-conjugated IL-10, Alexa
FluorH 647-conjugated IL-12, Pacific blue-conjugated IFN-c
(eBioscience), biotinylated anti-TGF-b1 Ab (Catalog number
BAF240, R & D Systems, Minneapolis, MN). For TGF-b1
staining, cells were restained with strepavidin-conjugated FITC
(Vector Laboratories). Alexa Fluor 647-conjugated anti-Foxp3 was
purchased from eBioscience. For cell sorting to isolate different cell
populations CB-SC-co-cultured, and control mouse lymphocytes,
or freshly-isolated mouse splenocytes were initially incubated with
CD16 Ab to block Fc receptor binding and then incubated with
different combination of antibodies such as FITC-conjugated CD4
and PE-Cy7-conjugated CD62L for 45 min at 4uC and subjected
to cell sorting using MoFlo (DakoCytomation). After confirming
the purity of the population (.98%), CD4
+CD62L
+ Tregs were
collected and used in different in vitro and in vivo experiments.
Quantitative real time PCR array
Expression of different mRNAs was analyzed by quantitative
real-time PCR. Total RNA was extracted using a Qiagen kit
(Valencia, CA). First-strand cDNAs were synthesized from total
RNA using QuantiTect Reverse Transcription kit according to the
manufacturer’s instructions (Qiangen, Valencia, CA). Real-time
PCR was performed on each sample in triplicate using the ABI
Prism 7900HT Fast Real-Time PCR System (Applied Biosystems,
CA), under the following conditions: 95uC for 15 min, then 40
cycles of 95uC for 15 s, and 60uC for 60 s, using the validated
gene-specific RT
2 PCR Primer sets for each gene (SuperArray,
Frederick, MD). Expression level of each gene, relative to b-actin
as an internal control, was determined. For real-time PCR array, a
mouse Th1-Th2-Th3 PCR array kit was used according to the
manufacturer’s instructions. The data were analyzed using a web-
based PCR array data analysis software provided by the
manufacturer (SuperArray).
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To treat established diabetic NOD mice, spleen lymphocytes
isolated from female NOD mice at 6–8 weeks of age were co-
cultured with CB-SC as described above [33]. After co-culture for
2–4 days, floating lymphocytes were collected for cell sorting as
described above. The purified CD4
+CD62L
+ Tregs (mCD4CD62L
Tregs, 3610
6 cells) were administered intraperitoneally into overt
diabetic NOD mice in 100 ml PBS/mouse (i.p., close to pancreas)
for the first dose, followed by a second dose at 2 million cells in
100 ml PBS/mouse (i.p., close to pancreas) one week later. Diabetic
mice injected with same volume of PBS served as one control.
Because of a marked decrease in lymphocyte viability after in vitro
culture in the absence of CB-SC, the sorted CD4
+CD62L
+ Tregs
from freshly-isolated mouse spleen lymphocytes without co-culture
with CB-SC ( control CD4CD62L Tregs) served as an additional
control. Blood glucose levels and body weights were monitored
twice a week until termination of the experiment. Three weeks after
initiation of treatment, glucose tolerance testing was done as
described below (n=3 for each group). At seven weeks after
treatment initiation, control mice were sacrificed for pathology due
to severe hyperglycemia (.600 mg/dL) and loss of body weight
(.20%). Diabetes-free mice following treatment with
mCD4CD62L Tregs were also sacrificed for histological examina-
tions.Tomeasureinsulin,bloodsampleswerecollectedfromthetail
vein. Bloodinsulin level was measured usingan ultrasensitive mouse
insulin enzyme-linked immunosorbent assay (EIA) kit (Alpco
Diagnostics, NH) following the manufacturer’s protocols. The
sensitivity of the assay is 0.019 ng/ml.
Intraperitoneal glucose tolerance testing (IPGTT)
Mice were fasted overnight (12 h), weighed and injected
intraperitoneally with a bolus of glucose (2 mg/g of body weight).
Blood was then drawn from a tail vein at 0, 10, 20, 30, 45, 60, 90,
and 120 min after glucose challenge. Glucose levels were
measured from whole tail vein blood as described above.
Immunohistochemistry and histology
Pancreata were fixed in 10% formaldehyde, processed, and
embedded in paraffin. Serial sections were cut at 5 mm thickness.
Immunostaining was performed as previously described with
minor modifications [3]. To block non-specific staining, sections
were incubated in a buffer containing 2.5% horse serum (Vector
Laboratories) for 20 min at room temperature. Primary antibodies
included guinea pig polyclonal anti-insulin Ab (DakoCytomation,
Carpinteria, CA), mouse anti-glucagon mAb (Sigma), mouse anti-
TGF-b1 mAb (Catalog number MAB240, 25% cross-reactivity
with latent form of TGF-b1, no cross-reactivity with TGF-b2,
,2% cross-reactivity with TGF-b3 and TGF-b5, R & D Systems),
mouse anti-SMAD4 mAb (Santa Cruz Biotechnology, Santa Cruz,
CA), rabbit anti-Ki67 mAb and rat anti-macrophage marker F4/
80 mAb (Novus Biologicals, Littleton, CO), and hamster anti-
mouse dendritic cell marker CD11c (BD Pharmingen). Second
Abs included Texas red-conjugated AffiniPure donkey anti-guinea
pig IgG, rhodamine-conjugated AffiniPure donkey anti-rabbit
IgG, AMCA AffiniPure Donkey Anti-Rabbit IgG, FITC-conju-
gated AffiniPure donkey anti-mouse IgG, and Cy5-conjugated
AffiniPure donkey anti-mouse IgG, AMCA AffiniPure Donkey
Anti-armenian hamster IgG, and Cy5-conjugated AffiniPure
donkey anti-rat IgG (Jackson ImmunoResearch Laboratories,
West Grove, PA). For non-fluorescence staining, after incubation
with primary antibodies, cells were stained with an ABC kit
(Vector Laboratories, Burlingame, CA). Biotinylated horse anti-
rabbit Ab and biotinylated goat anti-guinea Ab were purchased
from Vector Laboratories (Burlingame, CA). For isotype-matched
controls, mouse IgG1k was purchased from BD Biosciences, guinea
pig serum and rabbit IgG from Santa Cruz Biotechnology. For
pancreatic slides, we counterstained with hematoxylin (Sigma)
after immunostaining. For every experiment, isotype-matched
antibodies were used as negative controls. Cells were photo-
graphed with a Zeiss Axiocam Color Camera using Zeiss Axioskop
Histology/Digital Fluorescence microscope for HRP-immuno-
staining images, with Zeiss LSM 510 META confocal microscope
for fluorescence images.
To compare total b-cell mass after immunostaining with insulin
Ab, b-cell mass was measured and calculated by point-counting
morphometric analysis [35] using Image J software, download
from the NIH website (http://rsbweb.nih.gov/ij/).
To score insulitis, pancreatic sections from each experimental
group were stained with hematoxylin and eosin (H&E staining,
Sigma). At least 50 islets from 200 serial sections of each pancreas
were examined to evaluate the degree of leukocyte infiltration.
Insulitis was graded into five categories based on the extent of
intra-islet infiltration of leukocytes: no insulitis (no infiltration),
mild insulitis (,25% infiltration), moderate insulitis (25%,50%
infiltration), severe insulitis (50%,75% infiltrations), and pro-
found insulitis (.75% infiltration).
To determine apoptosis of infiltrated leukocytes, in situ cell death
detection kit (fluorescein) (Roche Applied Science, Indianapolis, IN)
was applied and performed using the manufacturer’s recommended
protocol. Cryosections (8 mm thickness) of frozen pancreata from
mCD4CD62L Treg-treated diabetic mice and control group were
prepared by using Microtome Cryostat HM 500 OM (Microm
International GmbH). To determine which cell type became
apoptotic, we use different markers including PE-conjugated CD4
mAb for CD4
+ T cells, PE-conjugated CD8 mAb for CD8
+ T cells,
PE-conjugated B220 mAb for B cells, and rat anti-mouse F4/80 mAb
for macrophages respectively in combination with TUNEL staining.
The mAbs to CD4, CD8 and B220 were from eBioscience.
Cryosections were initially detected with In Situ CellDeath Detection
Kit (Roche), followed by immunostaining with different monoclonal
Abs and imaging with a Zeiss LSM 510 META confocal microscope.
After double staining, positive cells were quantified directly on the
confocal microscope and/or on images. Cryosections incubated with
label solution without TUNEL reaction mixture and/or isotype-
matched IgG served as negative controls.
Cytokine assays
Cytokine levels in mouse plasma were quantified using
commercial ELISA kits following manufacturer’s instructions. We
purchased mouse IFN-c ELISA kit from Biolegend Inc.(San Diego,
CA), mouse IL-4 and IL-10 ELISA kits from Assay Designs (Ann
Arbor, MI), and TGF-b1 ELISA kit from Promega (Madison, WI).
Statistical analysis
Statistical analyses of data were performed by the two-tailed
Student’s t-test to determine statistical significance. Values are
given as mean6SD (standard deviation).
Supporting Information
Table S1 Modulation of Th1-Th2-Th3-related gene expressions
in CD4
+CD62L
+ Tregs after CB-SC co-culture. Mouse spleen
lymphocytes were isolated from female NOD mice (aged 6–8
weeks) and then co-cultured with CB-SC for 2 days at a ratio 1:10
of CB-SC:lymphocytes. Subsequently, the total lymphocytes were
harvested for cell sorting. Lymphocytes cultured in absence of CB-
SC served as control. Total RNAs were extracted from the
purified CD4
+CD62L
+ Tregs using a Qiagen kit (Valencia, CA).
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Reverse Transcription kit (Qiangen). For real-time PCR array,
mouse Th1-Th2-Th3 PCR array kits were used according to the
manufacturer’s instructions: 95uC for 15 min, then 40 cycles of
95uC for 15 s, and 60uC for 60 s, followed by a web-based PCR
array data analysis provided by the manufacturer (SuperArray).
Relative expression level of each gene was corrected for that of the
housekeeping gene b-actin as an internal control. Data represent
one of three independent experiments that gave similar results.
Fold change of expression in mCD4CD62L Tregs compared with
control CD4CD62L Tregs is shown.
Found at: doi:10.1371/journal.pone.0004226.s001 (0.03 MB
DOC)
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